Does Bevacizumab Cause Headache to the Onco-Surgeon? An Evidence-Based Review with Experience from A Tertiary Care Referral Oncology Center, India

Introduction:Bevacizumab is an antibody against VEGF-A which has recently been used in the pre-operative setting in malignancies, specially colo-rectal and ovarian cancers.We aim to review the surgical complications associated with such use of this molecule.Methods: Cases of ovarian and colorectal cancers that received preoperative Bevacizumab and underwent surgery at our center were included and their postoperative complications were evaluated.A review of literature was done for evaluating the complications associated with Bevacizumab.Cases and review: Four such cases were evaluated, all of whom developed postoperative complications.Patients developed perforations, urinary fistulae and incisional hernia postoperatively.Bevacizumab is known to cause GI perforations, genitourinary fistulae and delayed wound healing and such complications have been known to have a poor impact on quality of life and survival.Conclusion: Patients who have received Bevacizumab as Neo-adjuvant Therapy, should be considered as a special entity.A minimum of 8 weeks' time interval before major surgery is recommended after stopping Bevacizumab.

Authors

Publication Details

Journal
Mathews Journal of Case Reports
Published
2024-11-06
DOI
https://doi.org/10.30654/mjcr.10189
Primary Topic
Cancer Treatment and Pharmacology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Does Bevacizumab Cause Headache to the Onco-Surgeon? An Evidence-Based Review with Experience from A Tertiary Care Referral Oncology Center, India

Meredith Ray, Chinmay Bagla, Pranjal Banthia
Mathews Journal of Case Reports
Cancer Treatment and Pharmacology
article

Does Bevacizumab Cause Headache to the Onco-Surgeon? An Evidence-Based Review with Experience from A Tertiary Care Referral Oncology Center, India

Meredith Ray, Chinmay Bagla, Pranjal Banthia
article en

Abstract

Introduction:Bevacizumab is an antibody against VEGF-A which has recently been used in the pre-operative setting in malignancies, specially colo-rectal and ovarian cancers.We aim to review the surgical complications associated with such use of this molecule.Methods: Cases of ovarian and colorectal cancers that received preoperative Bevacizumab and underwent surgery at our center were included and their postoperative complications were evaluated.A review of literature was done for evaluating the complications associated with Bevacizumab.Cases and review: Four such cases were evaluated, all of whom developed postoperative complications.Patients developed perforations, urinary fistulae and incisional hernia postoperatively.Bevacizumab is known to cause GI perforations, genitourinary fistulae and delayed wound healing and such complications have been known to have a poor impact on quality of life and survival.Conclusion: Patients who have received Bevacizumab as Neo-adjuvant Therapy, should be considered as a special entity.A minimum of 8 weeks' time interval before major surgery is recommended after stopping Bevacizumab.

Mathews Journal of Case ReportsVol. 9(9)
Openalex Percentile: Top 58%
Cancer Treatment and Pharmacology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.